ophthalmologytimes1d
Regeneron reveals positive results from multiple trials evaluating Eylea HD (aflibercept) injection 8 mg
Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
Nasdaq3d
Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals announced positive ... in the retina often caused by poor blood sugar control in people with diabetes. The disease generally starts as nonproliferative diabetic ...
Morningstar8d
Regeneron's earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Mounjaro and Zepbound as treatments for obesity or diabetes. Regeneron is developing antibodies that may prevent that side effect, which is of particular concern for older patients. The Phase 2 ...
Nasdaq3d
Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...
FiercePharma8d
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs
As for revenue, Regeneron reported it at $3.79 billion for the fourth quarter, which was up 10% year over year. The company's full-year haul came in at $14.2 billion, which was an increase of 8%.
Long Island Press27d
MacArthur High School senior named Regeneron semifinalist
General Douglas MacArthur High School senior Melody Hong has been named one of 300 semifinalists in the 2025 Regeneron Science ... as Alzheimer’s and Type 1 diabetes. Through her innovative ...